Marchal, Gerard A.
van Putten, Maaike
Verkerk, Arie O.
Casini, Simona
Putker, Kayleigh
van Amersfoorth, Shirley C. M.
Aartsma-Rus, Annemieke
Lodder, Elisabeth M.
Remme, Carol Ann
Funding for this research was provided by:
ZonMw (91718361, 91714371)
Article History
Received: 14 September 2020
Accepted: 15 April 2021
First Online: 7 May 2021
Competing interests
: AAR discloses being employed by LUMC which has patents on exon skipping technology. As co-inventor of some of these patents AAR is entitled to a share of royalties. AAR further discloses being ad hoc consultant for PTC Therapeutics, Sarepta Therapeutics, Eisa Pharmaceuticals, WaVe Life Sciences, Astra Zeneca, Alpha Anomeric, CRISPR Therapeutics, BioMarin Pharmaceuticals Inc., Global Guidepoint and GLG consultancy, Grunenthal and BioClinica, being a member of the Duchenne Network Steering Committee (BioMarin) and of the scientific advisory boards of Sarepta Therapeutics, Silence Therapeutics ProQR and Philae Pharmaceuticals. Remuneration for these activities is paid to LUMC. LUMC also received speaker honoraria from PTC Therapeutics and BioMarin Pharmaceuticals. The other authors declare no conflict of interest.